Key Takeaways
- Execution rebound, not demand recovery: Revenue grew 22.8% QoQ as project execution improved sharply from a weak Q1, though it remains down 24% YoY against an unusually strong prior-year comparator.
- H2-weighted year intact: Management reaffirmed full-year guidance, with an INR 900 crore order book and ~30% of WIP material already positioned to support the back-ended delivery schedule.
- Margins doubled on operating leverage: EBITDA rose 110% QoQ and adjusted PAT nearly doubled to ₹8.45 crore, as the fixed cost base absorbed higher volumes; management targets an 8–9% adjusted PAT margin exit.
- Geopolitics is a cost, not a cancellation: West Asia instability raised freight, raw material and on-site security costs and slowed collections, but the pipeline has not shrunk and receivables are largely LC-backed.
- What to watch next quarter: Whether the Saudi JV is formally disclosed with a three-year growth vision, whether the European acquisition closes on its six-month timeline, and whether H2 revenue acceleration lands the 25–30% full-year growth target.
Execution & the H2 Bet
- Q1 was the trough: H1 performance was dragged by slow Q1 execution, geopolitical uncertainty and freight volatility across the GCC market; Q2 delivered a step-change in project throughput that management calls sustainable, not a one-off spike.
- H2 is not a recovery story: Management pushed back on the word "recovery," stating it already knows where H2 revenue is coming from and the task is managing customer expectations and delivery cadence.
- WIP pre-positioned: Approximately 30% of the work-in-progress material is already ready with an associate company and within the organization, de-risking the H2 execution ramp.
- Order book replenishment: The company added approximately INR 500 crore or INR 600 crore of new orders in the last six months, keeping the order book at INR 900 crore even as it executed existing work.
- Revenue recognition shift: Currently billing on shipment basis; working with auditors to move to a project-completion basis, targeted for FY28, which could alter the pattern of reported revenue.
Aman Anavkar: "Our guidance remains the same. We are very confident of the coming two quarters and our performance will speak."
Margin Mechanics
- Q2 leverage: Higher revenue flowed through a largely fixed cost base, more than doubling EBITDA QoQ; adjusted PAT nearly doubled to ₹8.45 crore.
- H1 cost headwinds: Enhanced security and protective measures for on-site personnel in the UAE added to installation costs; management said it would make the same call again.
- Three margin levers, each worth 2–3% over 3–5 years: Glocalization and tax optimization, alternative sourcing and procurement optimization, and the Green Shield initiative (solar and pre-engineered buildings increasing ticket sizes and execution efficiency).
- Raw material bet: Current orders are being priced on today's elevated raw material and freight costs; if the geopolitical situation normalizes and input costs fall, margins would get a tailwind from contracts already closed at higher prices, management indicated.
- Reference-project drag: A major vaccine project in India was taken at lower margin as a reference investment, weighing on blended margins; management frames this as a market-acquisition cost.
- No order-book margin disclosure: Management declined to quantify the average EBITDA margin embedded in the current order book, calling it a blend that varies by project and geography.
Aman Anavkar: "Right now the raw material costs are extremely high and we're closing orders based on these current prices. So later on when the war actualizes, freight goes down, RMC goes down, what kind of impact do you think will be on the margins for us?"
Geopolitics: Cost, Collections & Continuity
- West Asia impact is real but contained: Geopolitical uncertainty caused significant freight and raw material price volatility and delayed conversions, but management stated it has not cancelled or reduced the pipeline.
- Receivables up, but secured: Gross receivables rose to ₹235 crore (net ₹226 crore), driven by higher revenue and some collection slowness from geopolitical uncertainty; most are LC-backed and management expects significant collections in Q3 and Q4.
- Operating cash flow: H1 operating cash flow was approximately ₹41 crore; other current assets rose ₹40 crore, mainly from ₹38 crore in vendor advances for H2 material and equipment supply.
- UAE operations uninterrupted: Every site stayed running and every customer commitment was met despite the environment.
- People-first cost choice: The company absorbed higher installation costs to put enhanced security and protective measures in place for on-site teams.
Aman Anavkar: "There has definitely been an impact on the raw materials and the freight and the security measures that we talked about so that our people could perform and execute the projects smoothly. But each and every situation we have dealt with and there is a deliberate action that we are taking to ensure that our investors are secure, our company is secure and our people most important on site are secure."
Diversification: Geographies, Sectors & the Moat
- India turnaround: The home base now contributes 16% of that revenue, reflecting a real turnaround in our core standalone business.
- Deliberate geographic balance: Revenue is spread across Saudi Arabia, Africa and India so that no single market carries the company; each region is being ring-fenced for further growth.
- Saudi Arabia beyond pharma: Through the JV, the company is already taking orders from Saudi Aramco, SABIC and government projects, entering critical electromechanical and non-pharmaceutical sectors; a civil contract has been undertaken.
- CIS entry: A new turnkey design-and-build project marks the start of exploration in the CIS region.
- Non-pharma adjacencies: Data centres, renewable energy, cell and gene therapy, food and beverage, electrical industries, lens manufacturing, diaper manufacturing and baby products are all identified as natural adjacencies.
- Data centre bids live: Bids are already ongoing for data centre projects for critical infrastructure in the MENA region.
- The five-part moat: Management argues its competitive advantage rests on five pillars: in-house design and engineering, in-house manufacturing, project management and execution, in-house validation capability, and a 500-project, 2,000-installation reference base across 62 countries; the last, built over time, is the hardest to replicate.
Aman Anavkar: "Every project we deliver becomes that proof of reference. More references lead us to enter more geographies. ... Large projects build deeper customer trust and that trust brings the next round of projects. And this is the loop, this is the cycle, each time from a higher base."
M&A and Strategic Initiatives
- European acquisition (Italy): Due diligence is moving positively; expected to close within six months or in Q1 of next year; the target brings local manufacturing capability, product profile diversification, European market references, and a gateway to the US market.
- Acquisition unlocks development-finance projects: European investment banks funding projects in the Middle East and Africa often require procurement from Europe; management estimates the acquisition could lift success rates on such projects from 10% to 20%.
- Saudi JV: Discussions have progressed well; disclosure is expected in another quarter, and management committed that any JV announcement will come with a clear three-year vision at a specific growth rate.
- Khalapur land: Land acquired for INR 18.6 crore; the utilization plan will be disclosed by H2 results.
- IPO proceeds: Utilization to be completed by end of FY27; remaining free cash is earmarked for acquisitions, internal working capital, or cost and revenue optimization.
- PEB and civil works: Currently in an incubation period; management declined to quantify revenue expectations for FY27 or FY28, saying it will take a year to mature before specific numbers can be given.
Ashwani Singh: "Every JV will be announced with a clear vision for the next three years at a specific growth rate."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | 25% to 30% year-on-year growth | FY27 |
| Adjusted PAT margin exit | 8% to 9% | End of FY27 |
| European acquisition close | Due diligence positive; close expected | Within six months or Q1 FY28 |
| Saudi JV disclosure | Formal announcement with three-year growth vision | In another quarter |
| Revenue recognition method | Move to project-completion basis | Target FY28 |
| IPO proceeds utilization | Utilization to be completed | End of FY27 |
| Operating cash flow | Return to positive | By March (FY27 year-end) |
| Order book replenishment | INR 800–850 crore of new orders expected from Middle East and Africa | Next 12 months (conversion from hot pipeline) |
| Medium-term growth run rate | 25% to 30% annual growth | Next 3 to 5 years |
| ROE ambition | Grow to 20–30%+; "maybe we will be very close to 30% or more than 30%" | Two year, three year down the line |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹92.09 cr, +22.8% QoQ; down 24% YoY |
| Total income | ₹97.54 cr, +24.8% QoQ |
| EBITDA | ₹15.57 cr, +110% QoQ |
| EBITDA margin | 16%, expanded 647 bps QoQ |
| Reported PAT | ₹15.02 cr, vs ₹4.21 cr in Q1 FY27 |
| Exceptional item (net of tax) | ₹6.59 cr |
| Adjusted PAT | ₹8.45 cr, vs ₹4.21 cr in Q1 FY27 |
| Adjusted PAT margin | 9.2%, expanded 354 bps QoQ |
| Order book | Over ₹900 cr, approximately 2.2x last year's revenue |
| Additional pipeline beyond order book | ₹800 cr to ₹850 cr of added revenue expected over the next one year |
| Saudi Arabia revenue | ₹46.2 cr, +18.5% YoY |
| Africa revenue (Morocco, Kenya, Algeria) | ~₹47 cr combined |
| India revenue share | 16% of total revenue |
| Group receivables (gross) | ₹235 cr at September end; net ₹226 cr after ECL provisioning |
| Overdue receivables | ₹81 cr, of which ₹25 cr retention and ~₹50 cr being collected in coming months |
| Operating cash flow (H1 FY27) | ~₹41 cr |
| Cash and bank balance | More than ₹200 cr |
| Current ROE | ~9% |
| FY27 adjusted PAT margin target | 8% to 9% at year-end |
| Medium-term revenue growth target | 25% to 30% YoY |
| Hot pipeline | ₹3,600 cr to ₹4,000 cr |
| Expected order conversion in next 12 months | ₹800 cr to ₹850 cr |
| In-house manufactured share of design-and-build project | 30% |
| Global turnkey pharma and biotech market | $180 bn, growing at ~8% CAGR |
| Serviceable market (GCC, Africa, MENA) | $28 bn to $30 bn |
| Saudi Arabia pharma manufacturing investment (Vision 2030) | Over $15 bn |
| Africa medicine production investment (until 2040) | Over $60 bn |
| Fabtech scope of typical project spend | ~50% |
| Data centre scope of work for Fabtech | ~30% of total project value |
| Margin expansion target from strategic initiatives | 2% to 3% addition to PAT from each strategy over next 2–3 years |
| PEB share of project pipeline | ~20% |
| Land acquired at Khalapur | ₹18.6 cr |
| FY25 sales commission to G7 Universal LLC (related party) | ₹3.6 cr |